{"id":"NCT03532776","sponsor":"Dermax SA","briefTitle":"Comparison Between Podofilox Topical Gel 0.5% and Allergan's Condylox® Gel 0.5% for External Anogenital Warts","officialTitle":"A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo- Controlled, Study of Hyloris Developments' Podofilox Topical Gel 0.5% Compared to Allergan's Condylox® Gel 0.5% in Male and Female Patients With External Anogenital Warts.","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-04-20","primaryCompletion":"2018-12-02","completion":"2020-01-31","firstPosted":"2018-05-22","resultsPosted":"2021-07-27","lastUpdate":"2021-07-27"},"enrollment":466,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["External Anogenital Warts"],"interventions":[{"type":"DRUG","name":"Podofilox Gel 0.5%","otherNames":[]},{"type":"DRUG","name":"Condylox Topical Gel 0.5%","otherNames":[]},{"type":"DRUG","name":"Placebo Gel","otherNames":[]}],"arms":[{"label":"Podofilox Gel 0.5 %","type":"EXPERIMENTAL"},{"label":"Condylox Topical Gel 0.5%","type":"ACTIVE_COMPARATOR"},{"label":"Placebo Gel","type":"PLACEBO_COMPARATOR"}],"summary":"A clinical endpoint bioequivalence (BE) study for a Podofilox Gel 0.5% formulation for the treatment of external anogenital warts in comparison to Condylox® Gel 0.5% that follows the study design and recommendations according to Office of Generic Drugs (OGD) of U.S. Food and Drug Administration (FDA) Draft Guidance for Podofilox recommendations","primaryOutcome":{"measure":"Number and Percentage of Subjects With Total Disappearance of All Warts Within All Treated Areas.","timeFrame":"28 days.","effectByArm":[{"arm":"Podofilox Gel 0.5 %","deltaMin":100,"sd":null},{"arm":"Condylox Topical Gel 0.5%","deltaMin":102,"sd":null},{"arm":"Placebo Gel","deltaMin":12,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":17,"countries":["United States","Russia","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":201},"commonTop":["Application site erythema","Application site pain","Application site pruritus","Application site dryness","Application site erosion"]}}